ACS Publications. Most Trusted. Most Cited. Most Read

OR SEARCH CITATIONS

My Activity
Publications
CONTENT TYPES

Figure 1Loading Img
Download Hi-Res ImageDownload to MS-PowerPointCite This:J. Proteome Res. 2021, 20, 1, 49-59
RETURN TO ISSUEPREVReviewsNEXT

Overview of Targets and Potential Drugs of SARS-CoV-2 According to the Viral Replication

  • Yi Zhang
    Yi Zhang
    Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China
    More by Yi Zhang
    Orcidhttp://orcid.org/0000-0001-6801-8176
  •  and 
  • Liang V. Tang*
    Liang V. Tang
    Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China
    *Email: [email protected]. Tel.: +86 27 85726387. Fax: +86 27 85726387.
    More by Liang V. Tang
Cite this: J. Proteome Res. 2021, 20, 1, 49–59
Publication Date (Web):December 21, 2020
https://doi.org/10.1021/acs.jproteome.0c00526
Copyright © 2020 American Chemical Society
Request reuse permissions

    Article Views

    3926

    Altmetric

    -

    Citations

    27
    LEARN ABOUT THESE METRICS
    Other access options
    Get e-Alerts
    SUBJECTS:

    Abstract

    Abstract Image

    Since the novel coronavirus pandemic, people around the world have been touched in varying degrees, and this pandemic has raised a major global health concern. As there is no effective drug or vaccine, it is urgent to find therapeutic drugs that can serve to deal with the current epidemic situation in all countries and regions. We searched drugs and response measures for SARS-CoV-2 in the PubMed database, and then updated the potential targets and therapeutic drugs from the perspective of the viral replication cycle. The drug research studies of the viral replication cycle are predominantly focused on the process of the virus entering cells, proteases, and RdRp. The inhibitors of the virus entry to cells and RdRp, such as Arbidol, remdesivir, favipiravir, EIDD-2081, and ribavirin, are in clinical trials, while most of the protease inhibitors are mainly calculated by molecular docking technology, which needs in vivo and in vitro experiments to prove the effect for SARS-CoV-2. This review summarizes the drugs targeting the viral replication process and provides a basis and directions for future drug development and reuse on the protein level of COVID-19.

    KEYWORDS:

    Read this article

    To access this article, please review the available access options below.

    Get instant access

    Purchase Access

    Read this article for 48 hours. Check out below using your ACS ID or as a guest.

    Recommended

    Access through Your Institution

    You may have access to this article through your institution.

    Your institution does not have access to this content. You can change your affiliated institution below.

    Cited By

    This article is cited by 27 publications.

    1. Nuri Burak Kiremitler, Munteha Zeynep Kemerli, Nilgun Kayaci, Sultan Karagoz, Sami Pekdemir, Gokhan Sarp, Senem Sanduvac, Mustafa Serdar Onses, Erkan Yilmaz. Nanostructures for the Prevention, Diagnosis, and Treatment of SARS-CoV-2: A Review. ACS Applied Nano Materials 2022, 5 (5) , 6029-6054. https://doi.org/10.1021/acsanm.2c00181
    2. Aghnia Nabila Ananda, Triawanti Triawanti, Bambang Setiawan, Annisa Camellia Makati, Jasmine Aisyah Putri, Sentot Joko Raharjo. In silico study of the flavonoid compound of Sauropus androgynus leaves ON RNA-Dependent RNA polymerase (RdRp) SARS-CoV-2. Aspects of Molecular Medicine 2024, 3 , 100032. https://doi.org/10.1016/j.amolm.2023.100032
    3. Jun Wang, Qinghe Zhu, Xiaoxu Xing, Dongbo Sun. A Mini-Review on the Common Antiviral Drug Targets of Coronavirus. Microorganisms 2024, 12 (3) , 600. https://doi.org/10.3390/microorganisms12030600
    4. Yachan Feng, Haojie Zhang, Jiangtao Shao, Xiaolei Zhou, Yu Fu, Chao Du, Xueling Guo, Yingze Wang. Research Progress of Nanomaterials for Prevention, Diagnosis, and Treatment of SARS-CoV-2. BioNanoScience 2024, 395 https://doi.org/10.1007/s12668-024-01310-6
    5. Negar Omidkhah, Farzin Hadizadeh, Razieh Ghodsi. HDAC Inhibitors against SARS-CoV-2. Letters in Drug Design & Discovery 2024, 21 (1) , 2-14. https://doi.org/10.2174/1570180819666220527160528
    6. Aganze Gloire-Aimé Mushebenge, Samuel Chima Ugbaja, Nonkululeko Avril Mbatha, Rene B. Khan, Hezekiel M. Kumalo. Assessing the Potential Contribution of In Silico Studies in Discovering Drug Candidates That Interact with Various SARS-CoV-2 Receptors. International Journal of Molecular Sciences 2023, 24 (21) , 15518. https://doi.org/10.3390/ijms242115518
    7. , Stefanie Reis, Maria-Inti Metzendorf, Rebecca Kuehn, Maria Popp, Ildiko Gagyor, Peter Kranke, Patrick Meybohm, Nicole Skoetz, Stephanie Weibel. Nirmatrelvir combined with ritonavir for preventing and treating COVID-19. Cochrane Database of Systematic Reviews 2023, 2023 (11) https://doi.org/10.1002/14651858.CD015395.pub3
    8. Nimer Mehyar. Coronaviruses SARS-CoV, MERS-CoV, and SARS-CoV-2 helicase inhibitors: a systematic review of in vitro studies. Journal of Virus Eradication 2023, 9 (2) , 100327. https://doi.org/10.1016/j.jve.2023.100327
    9. Igor José dos Santos Nascimento, Ricardo Olimpio de Moura. Would the Development of a Multitarget Inhibitor of 3CLpro and TMPRSS2 be Promising in the Fight Against SARS-CoV-2?. Medicinal Chemistry 2023, 19 (5) , 405-412. https://doi.org/10.2174/1573406418666221011093439
    10. Andrey Bogoyavlenskiy, Madina Alexyuk, Pavel Alexyuk, Vladimir Berezin, Faisal A. Almalki, Taibi Ben Hadda, Alaa M. Alqahtani, Saleh A. Ahmed, Stefano Dall’Acqua, Joazaizulfazli Jamalis. Computer Analysis of the Inhibition of ACE2 by Flavonoids and Identification of Their Potential Antiviral Pharmacophore Site. Molecules 2023, 28 (9) , 3766. https://doi.org/10.3390/molecules28093766
    11. Anjali Jayasree Balakrishnan, Aswathi Kodenchery Somasundaran, Prajit Janardhanan, Rajendra Pilankatta. Peptides with antiviral activities. 2023, 219-235. https://doi.org/10.1016/B978-0-323-85682-9.00002-7
    12. Maame A. Korsah, Caleb Acquah, Michael K. Danquah. Transmission and intervention dynamics of SARS-CoV-2. 2023, 69-83. https://doi.org/10.1016/B978-0-323-91814-5.00009-X
    13. Weizhu Yan, Yanhui Zheng, Xiaotao Zeng, Bin He, Wei Cheng. Structural biology of SARS-CoV-2: open the door for novel therapies. Signal Transduction and Targeted Therapy 2022, 7 (1) https://doi.org/10.1038/s41392-022-00884-5
    14. Cong Sun, Chu Xie, Guo-Long Bu, Lan-Yi Zhong, Mu-Sheng Zeng. Molecular characteristics, immune evasion, and impact of SARS-CoV-2 variants. Signal Transduction and Targeted Therapy 2022, 7 (1) https://doi.org/10.1038/s41392-022-01039-2
    15. Sibei Lei, Xiaohua Chen, Jieping Wu, Xingmei Duan, Ke Men. Small molecules in the treatment of COVID-19. Signal Transduction and Targeted Therapy 2022, 7 (1) https://doi.org/10.1038/s41392-022-01249-8
    16. Yifan Zhang, Xinglong Zhang, Huiwen Zheng, Longding Liu. Subgenomic RNAs and Their Encoded Proteins Contribute to the Rapid Duplication of SARS-CoV-2 and COVID-19 Progression. Biomolecules 2022, 12 (11) , 1680. https://doi.org/10.3390/biom12111680
    17. Tino Emanuele Poloni, Matteo Moretti, Valentina Medici, Elvira Turturici, Giacomo Belli, Elena Cavriani, Silvia Damiana Visonà, Michele Rossi, Valentina Fantini, Riccardo Rocco Ferrari, Arenn Faye Carlos, Stella Gagliardi, Livio Tronconi, Antonio Guaita, Mauro Ceroni. COVID-19 Pathology in the Lung, Kidney, Heart and Brain: The Different Roles of T-Cells, Macrophages, and Microthrombosis. Cells 2022, 11 (19) , 3124. https://doi.org/10.3390/cells11193124
    18. , Stefanie Reis, Maria-Inti Metzendorf, Rebecca Kuehn, Maria Popp, Ildiko Gagyor, Peter Kranke, Patrick Meybohm, Nicole Skoetz, Stephanie Weibel. Nirmatrelvir combined with ritonavir for preventing and treating COVID-19. Cochrane Database of Systematic Reviews 2022, 2022 (9) https://doi.org/10.1002/14651858.CD015395.pub2
    19. Emiel Vanhulle, Joren Stroobants, Becky Provinciael, Anita Camps, Sam Noppen, Piet Maes, Kurt Vermeire. SARS-CoV-2 Permissive glioblastoma cell line for high throughput antiviral screening. Antiviral Research 2022, 203 , 105342. https://doi.org/10.1016/j.antiviral.2022.105342
    20. , Stefanie Reis, Maria Popp, Rebecca Kuehn, Maria-Inti Metzendorf, Ildiko Gagyor, Peter Kranke, Patrick Meybohm, Nicole Skoetz, Stephanie Weibel. Nirmatrelvir combined with ritonavir for preventing and treating COVID-19. Cochrane Database of Systematic Reviews 2022, 2022 (4) https://doi.org/10.1002/14651858.CD015395
    21. Sunil Thomas, Ann Abraham, Jeremy Baldwin, Sakshi Piplani, Nikolai Petrovsky. Artificial Intelligence in Vaccine and Drug Design. 2022, 131-146. https://doi.org/10.1007/978-1-0716-1884-4_6
    22. Amgad M. Rabie. RETRACTED ARTICLE: Discovery of (E)-N-(4-cyanobenzylidene)-6-fluoro-3-hydroxypyrazine-2-carboxamide (cyanorona-20): the first potent and specific anti-COVID-19 drug. Chemical Papers 2021, 75 (9) , 4669-4685. https://doi.org/10.1007/s11696-021-01640-9
    23. Mohsen Sisakht, Aida Solhjoo, Amir Mahmoodzadeh, Mohammad Fathalipour, Maryam Kabiri, Amirhossein Sakhteman. Potential inhibitors of the main protease of SARS-CoV-2 and modulators of arachidonic acid pathway: Non-steroidal anti-inflammatory drugs against COVID-19. Computers in Biology and Medicine 2021, 136 , 104686. https://doi.org/10.1016/j.compbiomed.2021.104686
    24. Andrea Madabeni, Pablo Andrei Nogara, Folorunsho Bright Omage, João Batista Teixeira Rocha, Laura Orian. Mechanistic Insight into SARS-CoV-2 Mpro Inhibition by Organoselenides: The Ebselen Case Study. Applied Sciences 2021, 11 (14) , 6291. https://doi.org/10.3390/app11146291
    25. Hani Nasser Abdelhamid, Gamal Badr. Nanobiotechnology as a platform for the diagnosis of COVID-19: a review. Nanotechnology for Environmental Engineering 2021, 6 (1) https://doi.org/10.1007/s41204-021-00109-0
    26. Shaomin Yan, Guang Wu. Potential 3‐chymotrypsin‐like cysteine protease cleavage sites in the coronavirus polyproteins pp1a and pp1ab and their possible relevance to COVID‐19 vaccine and drug development. The FASEB Journal 2021, 35 (5) https://doi.org/10.1096/fj.202100280RR
    27. Edoardo Biancalana, Martina Chiriacò, Paolo Sciarrone, Alessandro Mengozzi, Sandra Mechelli, Stefano Taddei, Anna Solini. Remdesivir, Renal Function and Short-Term Clinical Outcomes in Elderly COVID-19 Pneumonia Patients: A Single-Centre Study. Clinical Interventions in Aging 2021, Volume 16 , 1037-1046. https://doi.org/10.2147/CIA.S313028
    Download PDF

    Pair your accounts.

    Export articles to Mendeley

    Get article recommendations from ACS based on references in your Mendeley library.

    Pair your accounts.

    Export articles to Mendeley

    Get article recommendations from ACS based on references in your Mendeley library.

    You’ve supercharged your research process with ACS and Mendeley!

    STEP 1:
    Click to create an ACS ID

    Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.

    Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.

    Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.

    MENDELEY PAIRING EXPIRED
    Your Mendeley pairing has expired. Please reconnect